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     Pharmacovigilance is an activity that is of international 
significance. Until recently, pharmacovigilance has been confined 
mainly to detection of adverse drug events that were previously 
either unknown or poorly understood. Its main purpose was to 
contribute to a scientific understanding of the safety profile of  
drugs and to advise national regulatory authorities. Adverse Drug 
Reactions (ADRs) results in 0.3% to 7% of hospital admissions & 
forms 4th to 6th leading cause of death among hospitalized patients. 
Despite awareness, practicing doctors do not report ADRs due to 
their busy schedule. Hence there is a need for alternative approach 
to identify, analyze & report the ADRs in order to minimize the 
incidence. There is also a need to establish Pharmacovigilance 
centers across the country.         
     Objectives of Pharmacovigilance activities are to detect, 
assess, understand and prevent the adverse effects or any other 
drug-related problems. This conference brought together top 
pharmaceutical, biotechnical and regulatory representatives in a 
forum that addresses the key issues of the industry. The in-depth 
program covers the i) Detection, analysis and prevention of adverse 
drug reactions with case studies and industry experiences. ii) 
Understanding and learning the latest information, tools and 
knowledge to update with the currentand future market.  iii)  
Analyzing latest developments in pharmacovigilance which would 
shape any organization's risk management strategy.  
K.L.E.University’s Jawaharlal Nehru Medical College, Belgaum, 
Karnataka, India, Regional Medical Research Centre, Belgaum, [as 
part of ICMR Centenary Celebrations], Indian Pharmacological 
Society, and IPS, Belgaum Branch jointly organized  national 
symposium on Pharmacovigilance.  It aimed at disseminating 
information and to discuss and debate controversial issues in the 
continuously evolving field of pharmacology. There were 230 
participants from different healthcare institutes of India. Y.K.Gupta 
National Co-ordinator, Pharmacovigilance programme of India, 
(AIIMS, New Delhi) in his key note address spoke on 
“Pharmacovigilance Programme of India (PvPI): for safer medicine 
for Indian Population”. The goal of this programme has been to 
provide safer medicines for the Indian population. However, the 
program is faced with many challenges.  The number of patients in 
India is quite sizeable and the issues sometimes conflict between the 
need to provide access to medicines versus the need to provide 
safer medicines. On this occasion he announced the sanction of 
Pharmacovigilance Centre to the J.N.M.C. Belgaum. In his address 
he highlighted the importance of establishing pharmacovigilance 
centers in the medical colleges throughout India. The National 
Pharmacovigilance Centre at New Delhi is collaborating with the 
World Health Organization. Now the MCI (Medical Council of India) 
is regularizing Pharmacovigilance Centres in Medical Colleges. In 
the Inaugural address C.K.Kokate, (K.L.E University, Belgaum) 
explained the history of Indian pharmaceutical industries and 
compared the Indian status with those of other developing and 
developed countries. He also requested all the doctors to report 
adverse drug reactions, so that the database regarding adverse drug 
reactions can be strengthened which is a need of the time.  
     Neelima Kshirsagar (ICMR, Mumbai) spoke on “Post 
marketing surveillance studies”. Manufacturers should take a more 
proactive approach to drug safety rather than maintaining defensive 
tactics. This calls for a heightened level of product stewardship and 
recognition of responsibility to public and environmental health. B. 
Sesikeran (NIN, Hyderabad), spoke on “Safe limits of Nutrients” At 
present there are no specific limits on the levels of vitamins, minerals 
or other micronutrients which may be contained in supplements or 
fortified foods sold under food law, nor are there rules on the range 
of vitamins, minerals or other nutrients that they may contain. Anand 
Harugeri (Astra Zeneca Pharma India Ltd) spoke on “Case Handling 
Process in Pharmaceutical Industry”. A remarkable increase in use 
of drugs is seen in almost every country.  Modern medications tend 
not only to be expensive but also add appreciably to the cost of 
health services. The medical, social and economic consequences of 
drug utilization are equally important issues, which need evaluation 
from time to time.  It is necessary to ensure that drug use in a 
community is congruent with drug needs and confers maximum 
therapeutic benefits and minimal adverse reactions. A therapeutic 
audit is required at all levels of the therapeutic chain to ensure safe 
and effective medical care.  Medical doctors, pharmacists and 
public are requested to assess both the risks and benefits of drugs in 
a broad perspective. M.S.Ganachari (KLES College of Pharmacy, 
Belgaum) spoke on “ADR monitoring - our experience”. He 
elaborated on ICMR sponsored multicenter study on implementation 
and evaluation of ADR monitoring programme conducted for a period 
of 3 years. He explained about establishment of an ADR reporting 
system with the help of yellow card and ADR drop boxes.  Supriya 
Bhalerao (Nayar Hospital, Mumbai) spoke on “Issues in safety 
reporting of traditional medicines”.   She explained about ayurvedic 
concepts of ADR, safety and the need for Pharmacovigilance. She 
also elaborated the present issues in safety monitoring of traditional 
medicines which involve challenges in detection, assessment, 
prevention of ADRs and recommendations to overcome them. 
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     India's Drugs Control Department within the Ministry of Health 
& Family Welfare initiated the establishment of a nationwide network 
to build a comprehensive pharmacovigilance data system.  The 
National Pharmacovigilance Advisory of the Director General of 
Health Services and the Drug Controller General of India (DCGI), 
who functions as the member secretary of the Committee. Based at 
the Central Drugs Standard Control Organization, NPAC was 
assigned the primary responsibility of setting up the system to 
monitor the pharmacovigilance programme throughout the country. 
The National Pharmacovigilance Programme for India is sponsored 
by the World Health Organization (WHO) and is funded by the World 
Bank. 
     In the panel discussion resource persons discussed the on-
going pressing concerns faced in drug safety, addressing the risks, 
timeline and budget constraint, whilst effectively tackling key 
challenges in overcoming trials agreement and site contract 
negotiation hurdles. 
 
 
 
